News
Thesis The Simplify Intermediate Term Treasury Futures Strategy ETF (BATS:TYA) is a fixed income exchange traded fund. As per its literature: The Simplify Intermediate...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Yiannis Zourmpanos, founder of Yiazou IQ, an AI-driven stock research platform providing all-in-one stock reports. Experience: Previously worked...
News
This article was written by Follow Samuel Smith has a diverse background that includes being lead analyst and Vice President at several highly regarded...
News
This article was written by Follow Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish...
News
Thesis I have previously argued that UBS Group AG (NYSE:UBS) scored a ‘monster bargain’ buying Credit Suisse for about $3.25 billion. And following UBS...
News
Written by Nick Ackerman, co-produced by Stanford Chemist. This article was originally published to members of the CEF/ETF Income Laboratory on May 7th, 2023....
News
In a world where geopolitical tensions run high and national security becomes an ever-growing concern, defense companies play a crucial role. Among these industry...
News
I wrote about Tilray (NASDAQ:TLRY) just ahead of their fiscal Q3 report in mid-April and explained why I believe TLRY stock is headed lower....
News
Thesis My original recommendation to long Schrodinger (NASDAQ:SDGR) has worked out well with the share price exceeding my original target price back in January....
News
As ZIM Integrated Shipping Services (NYSE:ZIM) is set to report Q1’23 earnings on Monday before the market opens, the market still appears bullish on...
News
Introduction It’s time to discuss Steel Dynamics (NASDAQ:STLD). This Indiana-based steel giant is one of America’s best-performing industrial stocks and one of the few...
News
On our last coverage of Alibaba (NYSE:BABA), we acknowledged that the bulls were better setup, but did not attach a buy rating on that...
News
2023 will be a big year for AbbVie. The company’s transition from a Humira-dependent enterprise to one with multiple green shoots is here. Is...
